JP2023551194A5 - - Google Patents

Info

Publication number
JP2023551194A5
JP2023551194A5 JP2023530548A JP2023530548A JP2023551194A5 JP 2023551194 A5 JP2023551194 A5 JP 2023551194A5 JP 2023530548 A JP2023530548 A JP 2023530548A JP 2023530548 A JP2023530548 A JP 2023530548A JP 2023551194 A5 JP2023551194 A5 JP 2023551194A5
Authority
JP
Japan
Prior art keywords
substitution
modified igg
section
igg
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023530548A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023551194A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/060161 external-priority patent/WO2022109313A1/en
Publication of JP2023551194A publication Critical patent/JP2023551194A/ja
Publication of JP2023551194A5 publication Critical patent/JP2023551194A5/ja
Pending legal-status Critical Current

Links

JP2023530548A 2020-11-20 2021-11-19 ウシ科動物抗体バリアント Pending JP2023551194A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063116491P 2020-11-20 2020-11-20
US63/116,491 2020-11-20
PCT/US2021/060161 WO2022109313A1 (en) 2020-11-20 2021-11-19 Bovine antibody variants

Publications (2)

Publication Number Publication Date
JP2023551194A JP2023551194A (ja) 2023-12-07
JP2023551194A5 true JP2023551194A5 (https=) 2024-11-07

Family

ID=79018979

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023530548A Pending JP2023551194A (ja) 2020-11-20 2021-11-19 ウシ科動物抗体バリアント

Country Status (12)

Country Link
US (1) US20230416410A1 (https=)
EP (1) EP4247851A1 (https=)
JP (1) JP2023551194A (https=)
KR (1) KR20230110297A (https=)
CN (1) CN116615463A (https=)
AR (1) AR124130A1 (https=)
AU (1) AU2021382704A1 (https=)
BR (1) BR112023008490A2 (https=)
CA (1) CA3202089A1 (https=)
CO (1) CO2023007146A2 (https=)
MX (1) MX2023005896A (https=)
WO (1) WO2022109313A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4255933A4 (en) 2020-12-07 2025-07-23 Invetx Inc COMPOSITIONS FOR INCREASING THE HALF-LIFE OF A THERAPEUTIC AGENT IN LIVESTOCK ANIMALS AND METHODS OF USE
CN119730881A (zh) * 2022-08-05 2025-03-28 硕腾服务有限责任公司 牛抗体突变体
JP2025529206A (ja) * 2022-09-02 2025-09-04 ゾエティス・サービシーズ・エルエルシー 豚抗体変異体
CN119735654B (zh) * 2025-02-27 2025-07-01 浙江海隆生物科技股份有限公司 一种牛副流感病毒的亚单位hn蛋白制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
AU2005285347A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
ES2984405T3 (es) * 2012-09-13 2024-10-29 Bristol Myers Squibb Co Proteínas de dominio de andamio basadas en fibronectina que se unen a la miostatina
US11891440B2 (en) * 2015-10-05 2024-02-06 Circle33 Llc Antibodies with improved stability to intestinal digestion, polynucleotides thereof and methods of use thereof to treat disease

Similar Documents

Publication Publication Date Title
JP2023551194A5 (https=)
KR102855748B1 (ko) Sirp-알파 도메인 또는 이의 변이체를 갖는 구조체
AU2022206732A1 (en) Antibodies binding to CD3
TWI832824B (zh) 自單特異性抗體於活體內產生多特異性抗體之方法
JP7736688B2 (ja) 多重特異性抗原結合分子を製造するための方法
RU2016139006A (ru) Мультимерные fc-белки
RU2016139022A (ru) МУЛЬТИМЕРНЫЕ Fc-БЕЛКИ
CN118206639A (zh) 与经改造的Fc构建体相关的组合物和方法
JP2021500348A (ja) 単一特異性抗体から多重特異性抗体を生成させるための方法
JP2023522029A5 (https=)
WO2023186120A1 (zh) 抗血清白蛋白纳米抗体及其衍生物
CA3092387A1 (en) Anti-trem-1 antibodies and uses thereof
WO2022081794A1 (en) Shielded biologics with masking domains to shield antigen binding capability of biologics and uses thereof
TW202144431A (zh) 工程化抗her2雙特異性蛋白
JP7657591B2 (ja) 二重特異性抗原結合コンストラクト
CA3096791A1 (en) Cell engaging binding molecules
CN121057750A (zh) 结合ox40l的抗体和使用方法
IL298921A (en) Antibodies which bind to cancer cells and target radionuclides to said cells
JP2025528213A (ja) 複数ドメイン結合性分子
CN115151567A (zh) 治疗性Fc组合物的化学诱导结合和解离以及T细胞接合器与人血清白蛋白的化学诱导二聚化
WO2019178539A1 (en) Bispecific antibodies
US20210253741A1 (en) Bispecific antibodies
CN115551538A (zh) 干扰IL-1β受体信号转导的药剂
TW202146463A (zh) 蛋白酶加工的分子
RU2025102187A (ru) Мутанты бычьих антител